Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

trialsTrialRecruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A phase 1/2 trial of Pomalidomide, Dexamethasone, Azacitidine in hodgkin lymphoma and non-hodgkin lymphoma, run by CellCentric Ltd., now recruiting.

Overview Connected9

Overview

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies is a phase 1/2 interventional study registered as NCT04068597 by CellCentric Ltd., with 250 participants planned, started 2019-08-09 and due to reach its primary completion in 2027-03-31. Interventions recorded: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax. Conditions listed: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma. No results are recorded here; the registry entry is the source.

Setting

An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination in Patients With Advanced Haematological Malignancies.

Phase

Phase 1/2

Sponsor

CellCentric Ltd.

Registry

Started

2019-08-09

Enrolled

250 enrolled

Connected

Similar pages

Trial
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Trial
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Trial
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Trial
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Pomalidomide, Dexamethasone, Venetoclax, Multiple myeloma.
Trial
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Trial
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
Trial
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Pomalidomide, Dexamethasone, Multiple myeloma.
Trial
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.

cancers

Hodgkin lymphoma Multiple myeloma Non-Hodgkin lymphoma (all types)

drugs

ApprovedSmall-molecule hypomethylating agent (cytotoxic)

Azacitidine · Vidaza / Onureg (oral)

ApprovedProteasome inhibitor

Bortezomib · Velcade

ApprovedGlucocorticoid

Dexamethasone · Decadron (historic) / Hemady / Neofordex

ApprovedOral proteasome inhibitor (boronate)

Ixazomib · Ninlaro

ApprovedOral cereblon E3 ligase modulator (IMiD)

Pomalidomide · Pomalyst / Imnovid

ApprovedSmall-molecule BCL-2 inhibitor

Venetoclax · Venclexta

Evidence strength25/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
250 enrolled+12
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-16 · Jude Gomila · Header signup, trial wave 5 and Ask weighting · diff · file

Sources & links

ClinicalTrials.gov NCT04068597

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Hodgkin lymphoma
Non-Hodgkin lymphoma (all types)
Multiple myeloma

Products

Pomalidomide
Dexamethasone
Azacitidine
Venetoclax
Bortezomib
Ixazomib

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct04068597/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct04068597.

WebMCP tools registered on this page: onco_search, onco_get_entity.